Cover Image

Immature reticulocyte fraction: A novel biomarker of hemodynamic severity in pulmonary arterial hypertension

Fuente: Wiley Open Access

Saved in:

Bibliographic Details
Main Authors:	Adam J. Brownstein, Jared D. Wilkinson, Lloyd L. Liang, Richard N. Channick, Rajan Saggar, Airie Kim
Format:	Artículo Open Access
Published:	Wiley 2024
Subjects:	Pulmonary Circulation
Online Access:	Acceder al recurso
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

In Situ Pulmonary Artery Thrombosis and Low Flow Stasis Artifact in Parenchymal Lung Disease: An Under‐Recognized Phenomenon
by: Jennifer Mansour, et al.
Published: (2025)

Patients with CTEPH and mild hemodynamic severity of disease improve to a similar level of exercise capacity after pulmonary endarterectomy compared to patients with severe hemodynamic disease
by: Coen van Kan, et al.
Published: (2024)

Demographic, hemodynamic characteristics, and therapeutic trends of pulmonary hypertension patients: The Pulmonary Hypertension Mexican registry (REMEHIP)
by: Carlos Jerjes‐Sánchez, et al.
Published: (2024)

Pulmonary artery wave intensity analysis in pulmonary hypertension associated with heart failure and reduced left ventricular ejection fraction
by: Ivan H. W. Yim, et al.
Published: (2024)

Structured evaluation of unclear dyspnea–An attempt to shorten the diagnostic delay in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
by: Salaheldin Ahmed, et al.
Published: (2024)

The effects of oxygenation on acute vasodilator challenge in pulmonary arterial hypertension
by: Matthew D. Rockstrom, et al.
Published: (2024)

Use of combined chemotherapy and immunotherapy improves pulmonary arterial hypertension
by: Tejaswini P. Reddy, et al.
Published: (2024)

Right ventricular stroke work index in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: A retrospective observational study
by: Györgyi Csósza, et al.
Published: (2024)

Safety of inhaled nitric oxide withdrawal in severe chronic pulmonary hypertension
by: Gregorio Miguel Pérez‐Peñate, et al.
Published: (2024)

Factors associated with discontinuation of treatment for pulmonary arterial hypertension in the United States
by: Harrison W. Farber, et al.
Published: (2024)

Editorial on “Use of combined chemotherapy and immunotherapy improves pulmonary arterial hypertension”
by: Lindsay M. Forbes
Published: (2024)

Nationwide trends of balloon pulmonary angioplasty and pulmonary thromboendarterectomy for chronic thromboembolic pulmonary hypertension (2012–2019)
by: Adam S. Vohra, et al.
Published: (2024)

Predictors of early mortality after lung transplantation for idiopathic pulmonary arterial hypertension
by: Reda E. Girgis, et al.
Published: (2024)

Nanoparticle delivery of VEGF and SDF‐1α as an approach for treatment of pulmonary arterial hypertension
by: Victoria A. Guarino, et al.
Published: (2024)

An adult patient with pulmonary arterial hypertension, a NOTCH3 mutation, and leflunomide exposure
by: Elizabeth G. Fenner, et al.
Published: (2024)

Impact of selexipag maintenance dose on persistence, adherence, and hospitalization in US patients with pulmonary arterial hypertension
by: Charles D. Burger, et al.
Published: (2024)

Carnitine consumption and effect of oral supplementation in human pulmonary arterial hypertension: A pilot study
by: Evan L. Brittain, et al.
Published: (2024)

NT‐pro‐BNP is predictive of morbidity and mortality after pulmonary thromboendarterectomy and is independent of preoperative hemodynamics
by: Emanuel A. Keiler, et al.
Published: (2024)

Balloon pulmonary angioplasty for chronic thromboembolic pulmonary disease without pulmonary hypertension
by: Takatoyo Kiko, et al.
Published: (2024)

Impact of general anesthesia on the echocardiographic assessment of right ventricular function in pediatric patients with pulmonary arterial hypertension
by: Charles T. Simpkin, et al.
Published: (2024)

Editorial on “Characteristics and risk profiles of patients with pulmonary arterial or chronic thromboembolic pulmonary hypertension living permanently at >2500 m of high altitude in Ecuador”
by: Samantha Sharma, et al.
Published: (2024)

Younger age at initiation of subcutaneous treprostinil is associated with better response in pediatric Group 1 pulmonary arterial hypertension
by: Justin J. Kochanski, et al.
Published: (2024)

Pulmonary vascular dysfunction without pulmonary hypertension: A distinct phenotype in idiopathic pulmonary fibrosis
by: Steven D. Nathan, et al.
Published: (2024)

Association of risk assessment at diagnosis with healthcare resource utilization and health‐related quality of life outcomes in pulmonary arterial hypertension
by: Allan Lawrie, et al.
Published: (2024)

Two prospective, multicenter studies for the identification of biomarker signatures for early detection of pulmonary hypertension (PH): The CIPHER and CIPHER‐MRI studies
by: Allan Lawrie, et al.
Published: (2024)

Cardiopulmonary exercise testing and the 2022 definition of pulmonary hypertension
by: Dirk Habedank, et al.
Published: (2024)

Barriers to and facilitators of physical activity in pediatric pulmonary hypertension
by: Catherine M. Avitabile, et al.
Published: (2024)

Pulmonary hypertension patient perspectives toward pulmonary rehabilitation
by: Morgan Bailey, et al.
Published: (2024)

Excess healthcare resource utilization and costs for commercially insured patients with pulmonary arterial hypertension: A real‐world data analysis
by: Tracey Weiss, et al.
Published: (2024)

Selexipag in patients with pulmonary arterial hypertension associated with connective tissue disease (PAH‐CTD): Real‐world experience from EXPOSURE
by: Sean Gaine, et al.
Published: (2024)

PPARγ/ETV2 axis regulates endothelial‐to‐mesenchymal transition in pulmonary hypertension
by: Dong Hun Lee, et al.
Published: (2024)

Reorganized subtotal perfusion blockade of a pulmonary artery without hypertension after successfully lysed massive PE – A case report
by: Hendrik Scheidhauer, et al.
Published: (2024)

Evaluating the efficacy and safety of oral triple sequential combination therapy for treating patients with pulmonary arterial hypertension: A multicenter retrospective study
by: Qin‐Hua Zhao, et al.
Published: (2024)

Screening and diagnosis of pulmonary hypertension associated with chronic lung disease (PH‐CLD): A consensus statement from the pulmonary vascular research institute's innovative drug development initiative—group 3 pulmonary hypertension
by: P. Vitulo, et al.
Published: (2024)

Congruency between clinician‐assessed risk and calculated risk of 1‐year mortality in patients with pulmonary arterial hypertension: A retrospective chart review
by: Amresh Raina, et al.
Published: (2024)

Safety, tolerability, and efficacy of an in‐class combination therapy switch from bosentan plus sildenafil to ambrisentan plus tadalafil in children with pulmonary arterial hypertension
by: Cara Morgan, et al.
Published: (2024)

Early detection of pulmonary arterial hypertension through [18F] positron emission tomography imaging with a vascular endothelial receptor small molecule
by: Zhen Yang, et al.
Published: (2024)

THBS1 mediates hypoxia driven EndMT in pulmonary hypertension
by: Bingming Peng, et al.
Published: (2024)

COPD associated pulmonary hypertension: A post hoc analysis of the PERFECT study
by: Steven D. Nathan, et al.
Published: (2024)

CS1, a controlled‐release formulation of valproic acid, for the treatment of patients with pulmonary arterial hypertension: Rationale and design of a Phase 2 clinical trial
by: Raymond L. Benza, et al.
Published: (2024)